Astellas Pharma (ALPMY) Earnings Date, Estimates & Call Transcripts $10.61 +0.04 (+0.38%) As of 08/4/2025 03:59 PM Eastern Add Compare Share Share Earnings Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock Astellas Pharma Earnings Summary Astellas Pharma announced Q1 2026 earnings on July 30, 2025, reporting an EPS of $0.40, which topped the consensus estimate of $0.14 by $0.26. Quarterly revenue was reported to be $3.41 billion, above analysts' expectations of $3.20 billion. With a trailing EPS of $0.30 and a P/E Ratio of 35.37, Astellas Pharma's earnings are expected to grow 61.90% next year, from $0.42 to $0.68 per share. Q1 2026 Earnings ResourcesQ1 2026 Earnings ReportLatest Q1 2026 Earnings DateJul. 30EstimatedConsensus EPS (Jul. 30) $0.14 Actual EPS (Jul. 30) $0.40 Beat By $0.26 Actual Revenue (Jul. 30) $3.41B Get Astellas Pharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataALPMY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALPMY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Astellas Pharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $0.42 EPSNext Year EPS Consensus Estimate $0.68 EPS Astellas Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails7/30/2025Q1 2026$0.1356$0.40+$0.2644$0.26$3.20B$3.41B4/25/2025Q4 2025$0.1474$0.27+$0.1226$0.27$3.02B$3.22B2/4/2025Q3 2025-$0.30--$0.36--10/30/2024Q2 2025-$0.13-$0.13-$3.11B8/1/2024Q1 2025-$0.24-$0.35-$3.03B4/25/2024Q4 2024-$0.11-$0.34-$2.79B2/5/2024Q3 2024-$0.12-$0.17-$2.86B11/1/2023Q3 2023$0.17-$0.01 -$0.18-$0.01-$2.71B Astellas Pharma Earnings - Frequently Asked Questions When did Astellas Pharma announce their last quarterly earnings? Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earning data on Wednesday, July 30, 2025. Learn more on ALPMY's earnings history. Did Astellas Pharma beat their earnings estimates last quarter? In the previous quarter, Astellas Pharma (OTCMKTS:ALPMY) reported $0.40 earnings per share (EPS) to beat the analysts' consensus estimate of $0.14 by $0.26. Learn more on analysts' earnings estimate vs. ALPMY's actual earnings. How much revenue does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded annual revenue of $12.56 billion. How much profit does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded net income of $334.93 million. ALPMY has generated $0.30 earnings per share over the last four quarters. What is Astellas Pharma's price-to-earnings ratio? Astellas Pharma (OTCMKTS:ALPMY) has a trailing price-to-earnings ratio of 35.37 and a forward price-to-earnings ratio of 25.26. What is Astellas Pharma's EPS forecast for next year? Astellas Pharma's earnings are expected to grow from $0.42 per share to $0.68 per share in the next year, which is a 61.90% increase. More Earnings Resources from MarketBeat Related Companies INDV Earnings Date MEIP Earnings Date CHGCY Earnings Date ZTS Earnings Date DSNKY Earnings Date TAK Earnings Date ONC Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead? This page (OTCMKTS:ALPMY) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALPMY Stock Alerts